Abstract Roscovitine [CY-202,(R)-Roscovitine, Seliciclib] is a small molecule that inhibits
cyclin-dependent kinases (CDKs) through direct competition at the ATP-binding site. It is a …

Among the ten pharmacological inhibitors of cyclin-dependent kinases (CDKs) currently in
clinical trials, the purine roscovitine (CYC202, Seliciclib) is undergoing phase 2 trials against …

(R)-Roscovitine (CYC202) is often referred to as a" selective inhibitor of cyclin-dependent
kinases." Besides its use as a biological tool in cell cycle, neuronal functions, and apoptosis …

Roscovitine, a purine analogue, has been considered for the treatment of cancer. Anti-
cancer therapeutic efficacy is being evaluated in clinical trials. However, the mechanisms …

Deregulation of the cell cycle commonly occurs during tumorigenesis, resulting in
unrestricted cell proliferation and independence from mitogens. Cyclin-dependent kinase …

AIM: Phase I study of seliciclib (CYC202, R-roscovitine), an inhibitor of cyclin-dependent
kinases 2, 7 and 9, causing cell cycle changes and apoptosis in cancer cells. PATIENTS …

A new class of cell cycle inhibitors is currently entering clinical trials. These drugs exert their
activity by inhibition of cyclin-dependent kinases (cdk) and induce cell cycle arrest and …

Inhibition of cyclin-dependent kinases (CDKs) with small molecules has been suggested as
a strategy for treatment of cancer, based on deregulation of CDKs commonly found in many …

Pharmacological inhibitors of cyclin-dependent kinases (CDKs) have a wide therapeutic
potential. Among the CDK inhibitors currently under clinical trials, the 2, 6, 9-trisubstituted …

Seliciclib (R-Roscovitine) was identified as an inhibitor of CDKs and has undergone drug
development and clinical testing as an anticancer agent. In this review, the authors describe …